In a new study from Brigham and Women’s hospital, nearly 16,000 patient outcomes were analyzed that were diagnosed with COVID-19 and received the drug hydroxychloroquine.
Instead of improving, patients were four times more likely to experience dangerous heart irregularity, compared to those not teated with the antimalarial drug.
Patients in the study that were given hydroxychloroquine were also more likely to die.
The study is recently published in the medical journal The Lancet and is the most recent to address a hot topic about whether the medication, which is also prescribed to treat autoimmune disorders, should be used to treat COVID-19.
Mandeep R. Mehra, a corresponding study author and executive director of the Brigham’s Center for Advanced Heart Disease said the drug, or any regimen including a chloroquine, did not help “no matter which way you examine the data.”
Patients from six continents included
The researchers looked at data from 671 hospitals that included six continents …
Instead of improving, patients were four times more likely to experience dangerous heart irregularity, compared to those not teated with the antimalarial drug.
Patients in the study that were given hydroxychloroquine were also more likely to die.
The study is recently published in the medical journal The Lancet and is the most recent to address a hot topic about whether the medication, which is also prescribed to treat autoimmune disorders, should be used to treat COVID-19.
Mandeep R. Mehra, a corresponding study author and executive director of the Brigham’s Center for Advanced Heart Disease said the drug, or any regimen including a chloroquine, did not help “no matter which way you examine the data.”
Patients from six continents included
The researchers looked at data from 671 hospitals that included six continents …